Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

NCT ID: NCT05242510

Last Updated: 2025-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-27

Study Completion Date

2024-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study intends to determine the number and percent of subjects initially diagnosed with divergence excess exotropia which would be reclassified as simulated divergence excess exotropia if tested after 24 hours of monocular occlusion (patching) or after prism adaptation for the distance angle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exotropia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patching

Group Type EXPERIMENTAL

Patching

Intervention Type PROCEDURE

The subject will occlude the non-dominant eye for 24 hours.

Prism Adaptation

Group Type EXPERIMENTAL

Prism Adaptation

Intervention Type PROCEDURE

The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patching

The subject will occlude the non-dominant eye for 24 hours.

Intervention Type PROCEDURE

Prism Adaptation

The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with divergence excess exotropia according to standard criteria (see Study Procedures for specifics)
* No prior strabismus surgery
* Able to cooperate with testing (by examiner determination)

Exclusion Criteria

* Not amblyopic at the time of enrollment (best-corrected visual acuity in both eyes of 20/40 or better)
* Under 18 years of age. There is no lower age limit as long as the subject can cooperate for the required testing.
* No diagnosis of dissociated vertical deviation


* No diagnosis of divergence excess exotropia according to standard criteria (see Study Procedures for specifics)
* Prior strabismus surgery
* Unable to cooperate with testing (by examiner determination)
* Best-corrected visual acuity in either eye worse than 20/40
* 18 years of age or older
* Diagnosed with dissociated vertical deviation
Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Rochester

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Matthew Gearinger

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California Los Angeles

Los Angeles, California, United States

Site Status

Harvard University

Boston, Massachusetts, United States

Site Status

Ross Eye Institute

Buffalo, New York, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Queen's University

Kingston, Ontario, Canada

Site Status

LV Prasad Eye Institute

Hyderabad, , India

Site Status

Shamir Medical Center

Rishon LeZiyyon, Central District, Israel

Site Status

University of Milan

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada India Israel Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00006849

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

OCT-A and Amblyopia
NCT05223153 COMPLETED